---
layout: post
title: "Prospective Grant of an Exclusive Patent License: Small Cell Lung Cancer Subtyping Using Plasma Cell-Free Nucleosomes"
date: 2026-02-05 18:35:20 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-01019
original_published: 2023-01-20 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: Small Cell Lung Cancer Subtyping Using Plasma Cell-Free Nucleosomes

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** January 20, 2023 00:00 UTC
**Document Number:** 2023-01019

## Summary

The National Cancer Institute (NCI), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to Yissum Research and Development ("Yissum"), the technology transfer company of the Hebrew University of Jerusalem, a non-profit research institution located in Jerusalem, Israel for NCI's rights to the patent applications listed in the Supplementary Information section of this notice.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/01/20/2023-01019/prospective-grant-of-an-exclusive-patent-license-small-cell-lung-cancer-subtyping-using-plasma)
- API: https://www.federalregister.gov/api/v1/documents/2023-01019

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
